Drugs / Peptide-pulsed dendritic cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01410968 | Aug 2011 → Nov 2013 | malignant pancreatic neoplasm | Carolyn Britten | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00243594 | Sep 1999 → Jan 2009 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peptide-pulsed dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01410968 ↗ |
| Modality | Cell therapy | “Autologous monocyte-derived DCs are labeled with the clinically approved superparamagnetic iron oxide (SPIO) formulation Endorem and 111In-oxine and injected either in the skin...” NCT00243594 ↗ |
| Route | Other | “injected either in the skin or directly in lymph nodes under ultrasound guidance” NCT00243594 ↗ |